BGI Genomics Co Ltd

BGI Genomics released its 2026 semi-annual report, achieving operating revenue of 1.789 billion yuan, up 9.59% year on year. Net profit attributable to shareholders of the listed company was 47.4046 million yuan, up 718.24% year on year. The company's second-quarter net profit was 57 million yuan, while first-quarter net profit was negative 10 million yuan. Based on this calculation, second-quarter net profit turned from a loss to a profit quarter on quarter.

BGI Genomics has completed the third phase of its share buyback plan through centralized competitive trading. As of August 5, 2026, the company had repurchased a total of 6.7316 million shares, accounting for 1.61% of the current total share capital, with a total payment of 251 million yuan. The buyback implementation period was from July 13 to August 5, 2026, with the highest transaction price at 40.00 yuan per share and the lowest at 35.33 yuan per share. The actual total funds used exceeded the lower limit of 250 million yuan set in the buyback plan but did not exceed the upper limit of 500 million yuan. The repurchased shares will be used entirely for employee stock ownership plans or equity incentives, and will not carry voting rights or other shareholder rights during the holding period.

BGI Genomics announced that it has repurchased a total of 4.27 million shares through centralized competitive trading, accounting for 1.0208% of the total share capital. The total repurchase amount was 154 million yuan, with the repurchase price ranging from 35.33 yuan to 36.87 yuan per share. In the first quarter of 2026, the company achieved revenue of 809 million yuan and a net loss attributable to the parent company of 9.52 million yuan.

Bangkok Genomics Innovation Public Company Limited, or BKGI, is moving forward with expanding its comprehensive genetic testing platform by leveraging technology transfer from BGI Group, a global leader in genomics, to support the rapidly growing precision medicine and genetic testing market. Dr. Saowalak Dansakul, Chief Executive Officer, stated that the company aims to broaden its customer base to hospitals, public health agencies, and the private sector, while building recurring revenue from reagent sales and post-installation services for genetic testing equipment. Mr. Kittikun Rodrangnok, Chief Financial Officer, disclosed that BKGI has allocated an investment budget of approximately 40 million baht to expand its technology platform and is targeting revenue growth of 20 to 30 percent in 2026 compared to the previous year, driven by the expansion of precision medicine services and growth in recurring revenue.

The Fourth China International Supply Chain Expo has opened its Healthy Life Chain section, drawing more than 100 leading companies across Medical Technology, Quality Living, and Heritage Wellness zones. Global players GE Healthcare and Siemens Healthineers are demonstrating full China-for-China R&D and manufacturing capabilities, while AstraZeneca features an AI-powered drug discovery platform. Chinese innovators including BGI with a human genome foundation model and Longwood Valley with a domestically produced orthopedic surgical robot are also taking center stage. In consumer health, Procter & Gamble, L'Oréal, Panasonic, and Starbucks are showcasing digital intelligence and sustainability in their supply chains, with Starbucks connecting directly to Yunnan coffee farms for full traceability. Chinese TCM brands such as Guangzhou Phar. Holdings, Xin Bao Tang, and Zhendong Pharmaceutical are accelerating global expansion and vertical integration of authentic herb supply chains, alongside AI-driven diagnostic tools like smart pulse-taking devices.